262 related articles for article (PubMed ID: 10195869)
1. Cells in various benign and malignant conditions of the human prostate express different antigenic phenotypes.
Turhan OI; Aydin NE; Sariyüce O; Ozkan S
Int Urol Nephrol; 1998; 30(6):731-44. PubMed ID: 10195869
[TBL] [Abstract][Full Text] [Related]
2. Multidirectional differentiation in the normal, hyperplastic, and neoplastic human prostate: simultaneous demonstration of cell-specific epithelial markers.
Bonkhoff H; Stein U; Remberger K
Hum Pathol; 1994 Jan; 25(1):42-6. PubMed ID: 7508883
[TBL] [Abstract][Full Text] [Related]
3. Mesonephric remnant hyperplasia involving prostate and periprostatic tissue: findings at radical prostatectomy.
Chen YB; Fine SW; Epstein JI
Am J Surg Pathol; 2011 Jul; 35(7):1054-61. PubMed ID: 21606823
[TBL] [Abstract][Full Text] [Related]
4. Comparison of the basal cell-specific markers, 34betaE12 and p63, in the diagnosis of prostate cancer.
Shah RB; Zhou M; LeBlanc M; Snyder M; Rubin MA
Am J Surg Pathol; 2002 Sep; 26(9):1161-8. PubMed ID: 12218572
[TBL] [Abstract][Full Text] [Related]
5. Cytokeratin immunohistochemistry as a diagnostic tool for distinguishing malignant from benign epithelial lesions of the prostate.
Shah IA; Schlageter MO; Stinnett P; Lechago J
Mod Pathol; 1991 Mar; 4(2):220-4. PubMed ID: 1710806
[TBL] [Abstract][Full Text] [Related]
6. Changes in immunohistochemical staining of PSA, PAP, and TURP-27 following irradiation therapy for clinically localized prostate cancer.
Grob BM; Schellhammer PF; Brassil DN; Wright GL
Urology; 1994 Oct; 44(4):525-9. PubMed ID: 7524238
[TBL] [Abstract][Full Text] [Related]
7. Claudin-1 immunohistochemistry for distinguishing malignant from benign epithelial lesions of prostate.
Krajewska M; Olson AH; Mercola D; Reed JC; Krajewski S
Prostate; 2007 Jun; 67(9):907-10. PubMed ID: 17440968
[TBL] [Abstract][Full Text] [Related]
8. Validation of cytokeratin 5/6 as an effective substitute for keratin 903 in the differentiation of benign from malignant glands in prostate needle biopsies.
Abrahams NA; Ormsby AH; Brainard J
Histopathology; 2002 Jul; 41(1):35-41. PubMed ID: 12121235
[TBL] [Abstract][Full Text] [Related]
9. Neuroendocrine cells in benign prostatic hyperplasia and prostatic carcinoma: effect of hormonal treatment.
Guate JL; Escaf S; Menendez CL; del Valle M; Vega JA
Urol Int; 1997; 59(3):149-53. PubMed ID: 9428430
[TBL] [Abstract][Full Text] [Related]
10. Florid basal cell hyperplasia of the prostate: a histological, ultrastructural, and immunohistochemical analysis.
Yang XJ; Tretiakova MS; Sengupta E; Gong C; Jiang Z
Hum Pathol; 2003 May; 34(5):462-70. PubMed ID: 12792920
[TBL] [Abstract][Full Text] [Related]
11. [Pathologic characteristics of pseudohyperplastic prostatic adenocarcinoma].
Zhang HZ; Jiang ZM; Shi L
Zhonghua Bing Li Xue Za Zhi; 2007 Nov; 36(11):742-5. PubMed ID: 18307877
[TBL] [Abstract][Full Text] [Related]
12. P504S immunohistochemical detection in 405 prostatic specimens including 376 18-gauge needle biopsies.
Beach R; Gown AM; De Peralta-Venturina MN; Folpe AL; Yaziji H; Salles PG; Grignon DJ; Fanger GR; Amin MB
Am J Surg Pathol; 2002 Dec; 26(12):1588-96. PubMed ID: 12459625
[TBL] [Abstract][Full Text] [Related]
13. Diagnostic utility of immunohistochemical staining for p63, a sensitive marker of prostatic basal cells.
Weinstein MH; Signoretti S; Loda M
Mod Pathol; 2002 Dec; 15(12):1302-8. PubMed ID: 12481011
[TBL] [Abstract][Full Text] [Related]
14. Neuroendocrine expression in node positive prostate cancer: correlation with systemic progression and patient survival.
Bostwick DG; Qian J; Pacelli A; Zincke H; Blute M; Bergstralh EJ; Slezak JM; Cheng L
J Urol; 2002 Sep; 168(3):1204-11. PubMed ID: 12187268
[TBL] [Abstract][Full Text] [Related]
15. Endocrine-paracrine cell types in the prostate and prostatic adenocarcinoma are postmitotic cells.
Bonkhoff H; Stein U; Remberger K
Hum Pathol; 1995 Feb; 26(2):167-70. PubMed ID: 7532147
[TBL] [Abstract][Full Text] [Related]
16. Apoptosis incidence and protein expression of p53, TGF-beta receptor II, p27Kip1, and Smad4 in benign, premalignant, and malignant human prostate.
Zeng L; Rowland RG; Lele SM; Kyprianou N
Hum Pathol; 2004 Mar; 35(3):290-7. PubMed ID: 15017584
[TBL] [Abstract][Full Text] [Related]
17. Prostate specific membrane antigen expression in prostatic intraepithelial neoplasia and adenocarcinoma: a study of 184 cases.
Bostwick DG; Pacelli A; Blute M; Roche P; Murphy GP
Cancer; 1998 Jun; 82(11):2256-61. PubMed ID: 9610707
[TBL] [Abstract][Full Text] [Related]
18. Role of canine basal cells in prostatic post natal development, induction of hyperplasia, sex hormone-stimulated growth; and the ductal origin of carcinoma.
Leav I; Schelling KH; Adams JY; Merk FB; Alroy J
Prostate; 2001 May; 47(3):149-63. PubMed ID: 11351344
[TBL] [Abstract][Full Text] [Related]
19. Role of canine basal cells in postnatal prostatic development, induction of hyperplasia, and sex hormone-stimulated growth; and the ductal origin of carcinoma.
Leav I; Schelling KH; Adams JY; Merk FB; Alroy J
Prostate; 2001 Aug; 48(3):210-24. PubMed ID: 11494337
[TBL] [Abstract][Full Text] [Related]
20. Negative 34betaE12 staining in a small focus of atypical glands on prostate needle biopsy: a follow-up study of 332 cases.
Halushka MK; Kahane H; Epstein JI
Hum Pathol; 2004 Jan; 35(1):43-6. PubMed ID: 14745723
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
